Males, Antioxidants, and Infertility Trial (MOXI)
Males, Antioxidants, and Infertility (MOXI) Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90089
- Keck School of Medicine of University of Southern California
-
San Francisco, California, United States, 94115
- University of California San Francisco
-
Sunnyvale, California, United States, 94087
- Stanford University
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Augusta University
-
-
Michigan
-
Southfield, Michigan, United States, 48034
- Wayne State University
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
Charlotte, North Carolina, United States, 28204
- Carolinas Medical Center - Women's Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Pennsylvania State University
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Couple
- 12 or more months of infertility (primary or secondary)
- Heterosexual
- Cohabitating and able to have regular intercourse
Male:
- ≥ 18 years of age
At least one abnormal semen parameter on a semen analysis within the past 6 months:
- Sperm concentration ≤15 Million/ml
- Total motility ≤40%
- Normal morphology (Kruger) ≤4%
- DNA fragmentation (SCSA, DNA fragmentation index) >25%
Female:
- ≥18 years of age and ≤40 years of age
- For women ≥ 35 years of age, evidence of normal ovarian reserve as assessed by menstrual cycle day 3 (+/-2 days) FSH ≤10 IU/L with estradiol ≤ 70 pg/mL, AMH ≥ 1.0 ng/mL, OR antral follicle count >10 within one year prior to study initiation.
- Evidence of at least one patent fallopian tube as determined by an hysterosalpingogram or laparoscopy showing at least one patent fallopian tube or a saline infusion sonogram showing spillage of contrast material
- Regular cycles defined as ≥25 days and ≤35 days in duration
- Evidence of ovulation including biphasic basal body temperatures, positive ovulation predictor kits, or progesterone level ≥3 ng/ml.
Exclusion Criteria:
Couple:
- Previous sterilization procedures (vasectomy, tubal ligation). The prior procedure may affect study outcomes.
- Planning in vitro fertilization in the next 6 months
Male:
- Sperm concentration < 5 million/mL on screening semen analysis
- Current use of a medication or drug that would affect reproductive function or metabolism (see Appendix C for list)
- Current multivitamin or herb use (requires 1 month wash-out)
- Current serious medical illnesses, such as cancer, heart disease, or cirrhosis
- Current use of anticoagulants
- Untreated hypothyroidism
- Uncontrolled diabetes mellitus
Female:
- History of surgically or medically confirmed moderate or severe endometriosis
- Body mass index >35 kg/m2
- Currently pregnant
- History of polycystic ovarian syndrome
- Current serious medical illnesses, such as cancer, heart disease, or cirrhosis
- History of systemic chemotherapy or pelvic radiation
- Current use of a medication or drug that would affect reproductive function or metabolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Active Comparator: Antioxidant Supplement
Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
|
An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Live Birth Rate
Time Frame: up to 15 months
|
up to 15 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pregnancy Rate
Time Frame: up to 7 months
|
up to 7 months
|
|
|
Miscarriage Rate
Time Frame: up to 9 months
|
miscarriages per total number of pregnancies
|
up to 9 months
|
|
Time to Pregnancy
Time Frame: up to 7 months
|
Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as a human Chorionic Gonadotropin (hCG) value over 5 on 2 separate occasions.
|
up to 7 months
|
|
Change in Total Motile Sperm Count
Time Frame: baseline and 3 months
|
Samples will be assessed using a standard semen analysis
|
baseline and 3 months
|
|
Change in Deoxyribonucleic Acid (DNA) Fragmentation Index (DFI)
Time Frame: Baseline and 3 months
|
DFI is the ratio of damaged sperm to total sperm.
It is measured using Sperm Chromatin Structure Analysis (SCSA) which was performed on 5000 sperm per sample.
|
Baseline and 3 months
|
|
Change in Semen Total Motility
Time Frame: baseline and 3 months
|
Samples assessed using a standard semen analysis
|
baseline and 3 months
|
|
Change in Sperm Concentration
Time Frame: baseline and 3 months
|
Samples assessed using a standard semen analysis
|
baseline and 3 months
|
|
Change in Normal Morphology of Semen, Using World Health Organization (WHO) 5 Criteria
Time Frame: baseline and 3 months
|
Samples assessed using a standard semen analysis
|
baseline and 3 months
|
|
Change in Total Sperm Count
Time Frame: baseline and 3 months
|
Samples assessed using a standard semen analysis
|
baseline and 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Nanette Santoro, MD, University of Colorado, Denver
- Study Director: Marcelle Cedars, MD, University of California, San Francisco
- Study Director: Esther Eisenberg, MD, Eunice Kennedy Shriver National Institue of Child Health and Human Development
- Principal Investigator: Anne Z Steiner, MD, University of North Carolina
- Study Director: Michael P Diamond, MD, Augusta University
- Study Director: Richard S Legro, MD, Penn State University
- Study Director: Karl R Hansen, MD, University of Oklahoma
Publications and helpful links
General Publications
- Spitzer TL, Trussell JC, Coward RM, Hansen KR, Barnhart KT, Cedars MI, Diamond MP, Krawetz SA, Sun F, Zhang H, Santoro N, Steiner AZ. Biomarkers of Stress and Male Fertility. Reprod Sci. 2022 Apr;29(4):1262-1270. doi: 10.1007/s43032-022-00853-x. Epub 2022 Feb 1.
- Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS, Diamond MP, Krawetz SA, Usadi R, Baker VL, Coward RM, Huang H, Wild R, Masson P, Smith JF, Santoro N, Eisenberg E, Zhang H; Reproductive Medicine Network. The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertil Steril. 2020 Mar;113(3):552-560.e3. doi: 10.1016/j.fertnstert.2019.11.008. Epub 2020 Feb 25.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MOXI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.